Amphera's MesoPher Cell Therapy Demonstrates Favourable Safety and Promising Survival in a Phase II – PharmiWeb.com

Positive results from first cohort of 10 patients from REACtiVe study published in European Journal of Cancer
`S-HERTOGENBOSCH, the Netherlands–(BUSINESS WIRE)–Amphera B.V. announces positive REACtiVe Phase 2 study safety and efficacy data from the first cohort of 10 patients receiving Amphera’s MesoPher dendritic cell therapy. Patients, with resected pancreatic cancer who had completed standard-of-care chemotherapy, received 3 bi-weekly injections of MesoPher and booster injections at 4 and 7 months. The results from this first cohort have been published in the European Journal of Cancer1.
The latest REACtiVe data showed an average Overall Survival after surgery of approximately 36 months, with 8 of 10 patients alive, which is far beyond expected survival. No disease recurrence or any tumour progression is seen in 7 of 10 patients. Remarkably, the 3 patients with disease recurrence did not demonstrate rapid tumour growth. Furthermore, the safety profile of the treatment was favourable, with only transient grade 1 and 2 adverse events.
Prof. Casper van Eijck, principal investigator on the study and author on the paper said: “These latest data should be interpreted with care, as they are from a small cohort of patients, without a control arm. Nevertheless, these are very promising results that are exceeding disease progression and survival expectations for this group of patients. We hope to confirm these observations in the expansion cohort, with first results anticipated in the fourth quarter of this year.”
Ilona Enninga PhD, COO of Amphera said: “Pancreatic cancer is notoriously challenging to treat, as the historical medical literature illustrates. In this paper, the investigators consistently identified activated T-cells against autologous tumour. We believe this mechanism of action of MesoPher, the ability to activate T-cells, is central to the efficacy signal we are observing.”
Rob Meijer, CEO of Amphera said: “We are very excited by this new data showing impressive survival in this challenging disease setting. It is worth noting that MesoPher has also demonstrated encouraging safety and efficacy Phase I/II data in mesothelioma, providing strong proof of concept for the application of MesoPher in multiple cancer indications. In the fourth quarter of this year, we will also see results from our pivotal Phase II/III DENIM study with MesoPher in mesothelioma next to the expansion cohort of the REACtiVe Phase 2 study.”
Notes to Editors
About Amphera – www.amphera.nl
Amphera is a late-stage biotechnology company developing cell therapies to treat cancer. MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a lysate of tumour cell lines. PheraLys contains a broad repertoire of tumour-associated antigens, many of which are present in pancreatic cancer and other cancers.
Five clinical programmes are ongoing with MesoPher. The lead programme DENIM is a pivotal phase II/III study in pleural mesothelioma – a cancer of the lining of the lungs. The REACtiVe study is assessing MesoPher in resected pancreatic cancer. The REACtiVe-2 study assesses the safety and efficacy of a CD40 agonist in combination with MesoPher in patients with metastatic pancreatic cancer. In addition, MesoPher is investigated in abdominal mesothelioma and in pleural mesothelioma in combination with surgical resection. Amphera has obtained FDA and EMA orphan-designation for MesoPher for mesothelioma. Amphera is fully financed to complete its current clinical development programmes.
References:
– ENDS –
Amphera BV
Rob Meijer (CEO) [email protected]
Ilona Enninga (COO) [email protected]
Amphera media contact:
Adam Michael
80th Atom
+44 777 588 1813
[email protected]

PharmiWeb.com is Europe’s leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.

Read More

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


PharmiWeb.com is Europe’s leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
follow us
Copyright © 2022 PHARMIWEB.COM LIMITED, rights reserved by the relevant holders.
Version: 2022.3.2.1
You are leaving PharmiWeb.com
Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE
PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.
PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

source

Related posts

Leave a Reply

Your email address will not be published.